Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for cancer patients: drug may prevent chemo delays from low platelets

NCT ID NCT05772546

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times

Summary

This study tests whether the drug avatrombopag can safely raise low platelet counts caused by chemotherapy in people with gastrointestinal cancers. About 60 adults will receive either avatrombopag or a placebo. The goal is to see if the drug helps patients keep their platelet counts high enough to continue chemotherapy without delays or dose reductions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02215, United States

  • Oregon Health and Science University Hospital

    Portland, Oregon, 97239, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • University of Washington Fred Hutchinson Cancer Center

    Seattle, Washington, 98195, United States

Conditions

Explore the condition pages connected to this study.